EGFR vaccine cassette
JP2025534986A5Pending Publication Date: 2026-08-06GRITSTONE BIO INC
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2025517673
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-07-25
- Filing Date
- 2023-07-25
- Publication Date
- 2026-08-06
AI Technical Summary
Technical Problem
Current antigen prediction methods and vector systems for antigen delivery in cancer and infectious disease settings face challenges, particularly in overcoming pre-existing immunity to human viruses and improving vaccine potency and efficacy.
Method used
The development of antigen-encoding cassettes that encode distinct EGFR-associated MHC class I neoepitopes, such as EGFR_L858R, T790M, and E746-A750 deletion epitopes, with multiple repeats and linker sequences, for use in therapeutic vaccines, utilizing vectors like chimpanzee adenovirus and alphavirus vectors.
Benefits of technology
Enhances the immune response by inducing specific T-cell responses against cancer cells, overcoming pre-existing immunity and improving vaccine potency and efficacy.
✦ Generated by Eureka AI based on patent content.
Abstract
Disclosed herein are compositions comprising antigen-encoding nucleic acid sequences having multiple repeats of an EGFR neoepitope-encoding sequence, as well as methods related to the compositions, including nucleotides, cells, and their use as vaccines.
Need to check novelty before this filing date? Find Prior Art